Private equity firms vying for Perrigo’s pharma unit

Five private equity firms, including Apollo Global Management and CVC Capital Partners, are among the bidders for Perrigo’s prescription drug unit, according to Bloomberg.

Advertisement

Perrigo announced last year that it wants to sell off its Generic Rx unit to better focus on its consumer business. The unit could sell for more than $2.5 billion, according to people familiar with the matter cited by Bloomberg.

Carlyle Group, Altaris Capital Partners and Cerberus Capital Management also advanced to the next round of bidding for the unit.

Apollo has been increasingly interested in healthcare assets, having purchased Brentwood, Tenn.-based LifePoint Health for $5.6 billion late last year.

Read the full report here.

More articles on pharmacy:
7 drugs projected to become blockbusters by 2023
3 insulin manufacturers to testify at House panel April 10
Cigna-Express Scripts cap out-of-pocket 30-day insulin costs at $25

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.